REFERENCES
  1. Schutte J, Steegers E, Schuitemaker N, Santema J, de Boer K, Pel M, Vermeulen G, Visser W, van Roosmalen J, the Netherlands Maternal Mortality Committee. Rise in maternal mortality in the Netherlands. BJOG 2010; 117: 399 – 406
  2. Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM. The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertens. 2013; 3:44–47. doi: 10.1016/j.preghy.2012.11.001
  3. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstróm M et al. Predictive value of the sFlt-1/PlGF ratio in women with suspected preeclampsia. N Eng J Med 2016; 374: 13 - 22
  4. Schoofs K, Grittner U, Engels T, Pape J, Denk B, Henrich W and Verlohren S. The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med. 2014 Jan;42(1):61-8. doi: 10.1515/jpm-2013-0074
  5. Sabrià E, Lequerica-Fernández P, Lafuente P, Ángeles EE, Escudero AI, Martínez-Morillo E, Álvarez FV. Use of the sFlt-1/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible? Clin Chem Lab Med 2018; 56: 303 – 311
  6. VanWijk MJ, Kublickiene K, Boer K and VanBavel E. Vascular function in preeclampsia. Cardiovasc Res 2000; 47: 38 - 48
  7. Seong WJ, Kim SC, Hong DG, Koo TB, and Park IS. Amino-terminal pro-brain natriuretic peptide levels in hypertensive disorders complicating pregnancy. Hypertens Pregnancy 2011; 30: 287 - 294
  8. Álvarez-Fernández I, Prieto B, Rodríguez V, Ruano Y, Escudero AI and Álvarez FV. N-terminal pro B-type natriuretic peptide and angiogenic biomarkers in the prognosis of adverse outcomes in women with suspected preeclampsia. Clin Chim Acta 2016; 463: 150 - 157
  9. Afshani N, Moustaqim-Barrette A, Biccard BM, Rodseth RN, Dyer RA. Utility of B-type natriuretic peptides in preeclampsia: a systematic review. Int J Obstet Anesth 2013; 22: 96 - 103
  10. Resnik JL, Hong C, Resnik R, Kazanegra R, Beede J, Bhalla V, et al. Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 2005; 193: 450 – 454
  11. Johns, M.C., Stephenson, C. Amino-terminal pro-B-type natriuretic peptide testing in neonatal and pediatric patients. Am J Cardiol 2008; 101: 76 - 81
  12. Sabrià E, Lequerica-Fernández P, Lafuente-Ganuza P, Eguia-Ángeles E , Escudero AI, Martínez-Morillo E, Barceló C and Álvarez FV. Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1/placental growth factor ratio > 38 improves prediction of pre-eclampsia requiring delivery within 1 week: a longitudinal cohort study. Ultrasound Obstet Gynecol 2018; 51: 758 – 767
  13. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy: Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122: 122 – 131. DOI: 10.1097/01.AOG.0000437382.03963.88
  14. Zeger, S. L. and Liang, K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121 - 130
  15. R Development Core Team. R: A language and Environment for Statistical Computing, R Foundation for Statistical Computing 2009, Vienna, Austria. ISBN 3-900051-07-0. Available at: http://www.R-project.org. Accessed on 3/2/2015
  16. Bates D, Mächler M, Bolker BM and Walker SC. Fitting Linear Mixed-Effects Models Using lme4. Journal of Statistical Software October 2015. doi: 10.18637/jss.v067.i01
  17. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011; 7: 77
  18. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther. 2013;33(1):8-15. doi: 10.1159/000341264
  19. Serra B, Mendoza M, Scazzocchio E, Meler E, Nolla M, Sabrià E, Rodríguez I, Carreras E. A new model for screening for early-onset preeclampsia, Am J Obstet Gynecol (2020), doi: https://doi.org/10.1016/j.ajog.2020.01.020.
  20. Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377: 613–622
  21. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks’ gestation: a randomized controlled trial. Am J Obstet Gynecol. 1994;171(3):818–822.
  22. Odendaal HJ, Pattinson RC, Bam R, Grove D, Kotze TJ. Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks’ gestation: a randomized controlled trial. Obstet Gynecol. 1990;76(6):1070–1075.
  23. Vigil-De Gracia P, Reyes Tejada O, Calle Miñaca A, et al. Expectant management of severe preeclampsia remote from term: the MEXPRE Latin Study, a randomized, multicenter clinical trial. Am J Obstet Gynecol. 2013;209(5):425.e1–8
  24. Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012;206(1):58.e1–8.
  25. Enengl S, Mayer RB, Le Renard P-E, Shebl O, Arzt W, Oppelt P. Retrospective evaluation of established cut-off values for the sFlt- 1/PlGF ratio for predicting imminent delivery in preeclampsia patients Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health(2020), doi: https://doi.org/10.1016/jpregy.2020.01.009
  26. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabrià J et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014; 63: 346 – 352
  27. Cuckle H. Rational and irrational ratios. Ultrasound Obstet Gynecol 2016; 48: 275 – 278
  28. Verlohren S and Stepan H. Re: Rational and irrational ratios. Ultrasound Obstet Gynecol 2017; 49: 157 – 160
  29. McCarthy FP,Gill C, Seed PT, Bramham K, Chappell LC and Shennan AH. Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study. Ultrasound Obstet Gynecol 2019; 53: 62 – 67
  30. Verlohren S, Perschel FH, Thilaganathan B, Dröge LA, Henrich W, Busjahn A and Khalil A. Angiogenic Markers and Cardiovascular Indices in the Prediction of Hypertensive Disorders of Pregnancy. Hypertension. 2017 Jun;69(6):1192-1197.
  31. Di Pasquo E, Ghi T, Dall’asta A,Angeli L, Fieni S, Pedrazzi G, Frusca T. Maternal cardiac parameters can help in differentiating the clinical profile of preeclampsia and in predicting progression from mild to severe forms. AJOG 2019. doi: https://doi.org/10.1016/j.ajog.2019.06.029